Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
330.75
+0.68 (0.21%)
At close: Dec 5, 2025, 4:00 PM EST
330.98
+0.23 (0.07%)
After-hours: Dec 5, 2025, 7:56 PM EST
Elevance Health Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Elevance Health stock have an average target of 392.47, with a low estimate of 297 and a high estimate of 485. The average target predicts an increase of 18.66% from the current stock price of 330.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 8 | 8 | 8 | 6 | 6 |
| Hold | 2 | 3 | 3 | 3 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 15 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $380 → $400 | Strong Buy | Maintains | $380 → $400 | +20.94% | Nov 26, 2025 |
| Mizuho | Mizuho | Buy Maintains $420 → $400 | Buy | Maintains | $420 → $400 | +20.94% | Nov 4, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $384 → $394 | Buy | Maintains | $384 → $394 | +19.12% | Oct 28, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $330 → $380 | Strong Buy | Maintains | $330 → $380 | +14.89% | Oct 23, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $412 → $403 | Buy | Maintains | $412 → $403 | +21.84% | Oct 22, 2025 |
Financial Forecast
Revenue This Year
200.09B
from 176.81B
Increased by 13.17%
Revenue Next Year
207.42B
from 200.09B
Increased by 3.66%
EPS This Year
30.29
from 25.68
Increased by 17.94%
EPS Next Year
27.66
from 30.29
Decreased by -8.67%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 211.1B | 228.8B | |||
| Avg | 200.1B | 207.4B | |||
| Low | 192.7B | 193.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.4% | 14.3% | |||
| Avg | 13.2% | 3.7% | |||
| Low | 9.0% | -3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 31.68 | 33.17 | ||||
| Avg | 30.29 | 27.66 | ||||
| Low | 29.08 | 24.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 23.4% | 9.5% | ||||
| Avg | 17.9% | -8.7% | ||||
| Low | 13.2% | -20.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.